Average Co-Inventor Count = 4.13
ph-index = 23
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Isis Pharmaceuticals, Inc. (43 from 1,035 patents)
2. Ionis Pharmaceuticals, Inc. (40 from 270 patents)
3. University of Texas System (3 from 5,444 patents)
4. Merck + Co., Inc. (2 from 4,770 patents)
5. Alnylam Pharmaceuticals, Inc. (2 from 443 patents)
6. Academisch Ziekenhuis Leiden (2 from 47 patents)
7. Other (1 from 832,680 patents)
8. Merck Sharp + Dohme Corp. (1 from 2,405 patents)
9. Astrazeneca Ab (1 from 1,500 patents)
10. Lonis Pharmaceuticals, Inc. (1 from 5 patents)
11. Alaylam Pharmacueuticals, Inc. (1 from 1 patent)
12. Academisch Ziekenhuis Leiden (h.o.d.n. Lumc) (37 patents)
87 patents:
1. 12291709 - Compositions and methods for modulating apolipoprotein (a) expression
2. 12115225 - GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
3. 11851655 - Compositions and methods for modulating apolipoprotein (a) expression
4. 11732265 - Compositions and methods for modulating complement factor B expression
5. 11459564 - Modulation of frataxin expression
6. 11414657 - Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
7. 11312964 - Compositions and methods for modulating growth hormone receptor expression
8. 11299736 - Conjugated antisense compounds and their use
9. 11293025 - Compositions and methods for modulating Ataxin 3 expression
10. 11268094 - 5' modified nucleosides and oligomeric compounds prepared therefrom
11. 11260073 - Compounds and methods for modulating C90RF72
12. 11104899 - Oligomer-conjugate complexes and their use
13. 11084844 - Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
14. 10927372 - Compositions and methods for modulating apolipoprotein C-III expression
15. 10883104 - Compositions and methods for modulating apolipoprotein (a) expression